Antiphospholipid syndrome

Michelle Petri

doi:10.1016/j.trsl.2020.04.006

Antiphospholipid syndrome

Michelle Petri

School of Medicine

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.

Original language	English (US)
Pages (from-to)	70-81
Number of pages	12
Journal	Translational Research
Volume	225
DOIs	https://doi.org/10.1016/j.trsl.2020.04.006
State	Published - Nov 2020

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Physiology (medical)
Biochemistry, medical

Access to Document

10.1016/j.trsl.2020.04.006

Cite this

@article{d6f796fb15794391baf3e4a079dff7b7,

title = "Antiphospholipid syndrome",

abstract = "Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.",

author = "Michelle Petri",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = nov,

doi = "10.1016/j.trsl.2020.04.006",

language = "English (US)",

volume = "225",

pages = "70--81",

journal = "Translational Research",

issn = "1931-5244",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Antiphospholipid syndrome

AU - Petri, Michelle

PY - 2020/11

Y1 - 2020/11

N2 - Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.

AB - Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe pre-eclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=85086036218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086036218&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2020.04.006

DO - 10.1016/j.trsl.2020.04.006

M3 - Review article

C2 - 32413497

AN - SCOPUS:85086036218

SN - 1931-5244

VL - 225

SP - 70

EP - 81

JO - Translational Research

JF - Translational Research

ER -

Antiphospholipid syndrome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this